BiocardiaInc Company Insiders
| BCDA Stock | USD 0.37 0.01 2.78% |
BiocardiaInc employs about 16 people. The company is managed by 17 executives with a total tenure of roughly 146 years, averaging almost 8.0 years of service per executive, having 0.94 employees per reported executive. Analysis of BiocardiaInc's management performance can provide insight into the company performance.
| Peter Altman CEO President CEO, Principal Executive Officer, Director |
| Simon Stertzer Chairman Chairman of the Board |
BiocardiaInc |
BiocardiaInc Management Team Effectiveness
The company has return on total asset (ROA) of (1.1389) % which means that it has lost $1.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0362) %, meaning that it created substantial loss on money invested by shareholders. BiocardiaInc's management efficiency ratios could be used to measure how well BiocardiaInc manages its routine affairs as well as how well it operates its assets and liabilities.BiocardiaInc Workforce Comparison
BiocardiaInc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 787. BiocardiaInc holds roughly 16.0 in number of employees claiming about 2.03% of equities under Health Care industry.
BiocardiaInc Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BiocardiaInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on BiocardiaInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BiocardiaInc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jay Moyes over two weeks ago Acquisition by Jay Moyes of 12434 shares of BiocardiaInc at 4.43 subject to Rule 16b-3 | ||
Simon Stertzer over a month ago BiocardiaInc exotic insider transaction detected | ||
Simon Stertzer over six months ago Acquisition by Simon Stertzer of 12434 shares of BiocardiaInc subject to Rule 16b-3 | ||
Simon Stertzer over six months ago Acquisition by Simon Stertzer of 64212 shares of BiocardiaInc subject to Rule 16b-3 |
BiocardiaInc Notable Stakeholders
A BiocardiaInc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BiocardiaInc often face trade-offs trying to please all of them. BiocardiaInc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BiocardiaInc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Altman | President CEO, Principal Executive Officer, Director | Profile | |
| Simon Stertzer | Chairman of the Board | Profile | |
| Richard Allen | Vice President of quality | Profile | |
| Mark Schwartz | Vice President - Clinical Affairs | Profile | |
| Phil Pesta | Vice President - Operations | Profile | |
| David McClung | Principal Financial and Accounting Officer, Vice President - Finance | Profile | |
| Thomas Quertermous | Director | Profile | |
| Richard Pfenniger | Director | Profile | |
| Fernando Fernandez | Director | Profile | |
| Allan Tessler | Director | Profile | |
| Richard Krasno | Director | Profile | |
| Jay Moyes | Director | Profile | |
| Edward Gillis | Senior Devices | Profile | |
| Ian McNiece | Chief Officer | Profile | |
| Sujith MBBS | Chief Regulatory | Profile | |
| Henricus Duckers | Chief Medical Officer | Profile | |
| Sujith Shetty | Chief Regulatory | Profile |
About BiocardiaInc Management Performance
The success or failure of an entity such as BiocardiaInc often depends on how effective the management is. BiocardiaInc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BiocardiaInc management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BiocardiaInc management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
The data published in BiocardiaInc's official financial statements usually reflect BiocardiaInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of BiocardiaInc. For example, before you start analyzing numbers published by BiocardiaInc accountants, it's critical to develop an understanding of what BiocardiaInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of BiocardiaInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BiocardiaInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BiocardiaInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BiocardiaInc. Please utilize our Beneish M Score to check the likelihood of BiocardiaInc's management manipulating its earnings.
BiocardiaInc Workforce Analysis
Traditionally, organizations such as BiocardiaInc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BiocardiaInc within its industry.BiocardiaInc Manpower Efficiency
Return on BiocardiaInc Manpower
| Revenue Per Employee | 29.8K | |
| Revenue Per Executive | 28.1K | |
| Net Loss Per Employee | 723.2K | |
| Net Loss Per Executive | 680.6K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BiocardiaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade BiocardiaInc Stock refer to our How to Trade BiocardiaInc Stock guide.Note that the BiocardiaInc information on this page should be used as a complementary analysis to other BiocardiaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for BiocardiaInc Stock analysis
When running BiocardiaInc's price analysis, check to measure BiocardiaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BiocardiaInc is operating at the current time. Most of BiocardiaInc's value examination focuses on studying past and present price action to predict the probability of BiocardiaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BiocardiaInc's price. Additionally, you may evaluate how the addition of BiocardiaInc to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is BiocardiaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BiocardiaInc. If investors know BiocardiaInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BiocardiaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BiocardiaInc is measured differently than its book value, which is the value of BiocardiaInc that is recorded on the company's balance sheet. Investors also form their own opinion of BiocardiaInc's value that differs from its market value or its book value, called intrinsic value, which is BiocardiaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BiocardiaInc's market value can be influenced by many factors that don't directly affect BiocardiaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BiocardiaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if BiocardiaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BiocardiaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.